Item 2.02. Results of Operations and Financial Condition.

On November 9, 2009, Molecular Insight Pharmaceuticals, Inc. (the "Company") issued a press release announcing the financial results of the Company for the three and nine months ended September 30, 2009. A copy of the press release is furnished with this report as Exhibit 99.1 to this Form 8-K.

Item 8.01. Other Events.

On November 9, 2009, the Company announced certain updates of the Company's clinical and business developments and financing plan in the same press release that announced the financial results. A copy of this press release is furnished with this Current Report on Form 8-K and attached hereto as Exhibit 99.1.

Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is furnished pursuant to Item 2.02 and Item 8.01:

99.1 Press Release of Molecular Insight Pharmaceuticals, Inc. dated November 9, 2009.

---

Table of Contents